We use cookies to improve your experience on our website. Read about how we use cookies and how you can control them by reviewing the Cookie section of our Privacy Policy. By continuing to use this website, you consent to our use of these cookies.

  • BMS Science Search BMS recruiting trials
  • Bolder Science Powered by ClinicalTrials.gov
    This website is intended for healthcare professionals
    This website is intended for healthcare professionals
  • Sign Up
  • Log In
  • Sign up for an account to save the trials you’re interested in following. You can use one account across both BMS Science and Bolder Science to track clinical trials worldwide.
Sign up for an account to save the trials you’re interested in following. You can use one account across both BMS Science and Bolder Science to track clinical trials worldwide.
 
  • Clinical Trials
  • Molecular Pathways
  • About BMS Science
Cancel

    Welcome to BMS Science

    BMS Science is a fast and easy way to find our recruiting and soon-to-be recruiting trials. Search clinical trials simply by entering a disease area of interest and/or a location.

    Search BMS Recruiting Clinical Trials

    • Current Location
    Clear search

    Interested in looking outside of BMS-sponsored trials?
    Visit BolderScience.com to search all worldwide trials.

    Choose filters to find specific trials in the BMS pipeline.

    Filter trials by:

    STATUS AND PHASE

    STATUS

    PHASE

    Clear all
    trials No trials are available
    at this time.
    Check back for
    updates.
    Status
    • Not Yet Recruiting
    • Recruiting
    Phase
    • Phase 1
    • Phase 2
    • Phase 3
    • Phase 4

    Clinical trial information is sourced from ClinicalTrials.gov. Information is updated manually as clinical trials are published. The efficacy and safety of the agents and/or uses under investigation have not been established. There is no guarantee that the agents will receive health authority approval or become commercially available in any country for the uses being investigated.

    Interested in looking outside of BMS-sponsored trials?
    Visit BolderScience.com to search all worldwide trials.

    Cardiovascular

    Genetic Dilated Cardiomyopathy

    Area of Research

    Phase*

    Danicamtiv
    Selective Cardiac Myosin Inhibitor
    Area of Research: Genetic Dilated Cardiomyopathy
    Phase 2
    • View trial
      Save trial
    Clinical Trials For: Danicamtiv, Selective Cardiac Myosin Inhibitor in Genetic Dilated Cardiomyopathy
    • Exploratory Study of Danicamtiv in Patients With Primary Dilated Cardiomyopathy (DCM) Due to Genetic Variants

      Recruiting, Phase 2

      NCT04572893
      NCT04572893
    Expand All Displaying 5 of 11

    Genetic Dilated Cardiomyopathy

    No trials are available at this time. Check back for updates.

    Heart Failure

    Area of Research

    Phase*

    Mavacamten
    Selective Cardiac Myosin Inhibitor
    Area of Research: Heart Failure With Preserved Ejection Fraction
    Phase 2
    • View trial
      Save trial
    Clinical Trials For: Mavacamten, Selective Cardiac Myosin Inhibitor in Heart Failure With Preserved Ejection Fraction
    • A Study of Mavacamten in Participants With HFpEF and Chronic Elevation of cTnI and/or NT-proBNP

      Recruiting, Phase 2

      NCT04766892
      NCT04766892
    Expand All Displaying 5 of 11

    Heart Failure

    No trials are available at this time. Check back for updates.

    Obstructive Hypertrophic Cardiomyopathy Septal Reduction Therapy eligible

    Area of Research

    Phase*

    Expand All Displaying 5 of 11

    Obstructive Hypertrophic Cardiomyopathy Septal Reduction Therapy eligible

    No trials are available at this time. Check back for updates.

    Pediatric Heart Disease

    Area of Research

    Phase*

    Expand All Displaying 5 of 11

    Pediatric Heart Disease

    No trials are available at this time. Check back for updates.

    Thrombotic Disorders

    Area of Research

    Phase*

    Expand All Displaying 5 of 11

    Thrombotic Disorders

    No trials are available at this time. Check back for updates.

    Venous Thromboembolism Treatment (Pediatric)

    Area of Research

    Phase*

    Apixaban
    Factor Xa Inhibitor
    Area of Research: Pediatric Subjects Requiring Anticoagulation for the Treatment of a VTE
    Phase 4
    • View trial
      Save trial
    Clinical Trials For: Apixaban, Factor Xa Inhibitor in Pediatric Subjects Requiring Anticoagulation for the Treatment of a VTE
    • Apixaban for the Acute Treatment of Venous Thromboembolism in Children

      Recruiting, Phase 4

      NCT02464969
      NCT02464969
    Expand All Displaying 5 of 11

    Venous Thromboembolism Treatment (Pediatric)

    No trials are available at this time. Check back for updates.

    VTE prevention in pediatrics with ALL

    Area of Research

    Phase*

    Expand All Displaying 5 of 11

    VTE prevention in pediatrics with ALL

    No trials are available at this time. Check back for updates.

    COVID-19

    COVID-19 (General)

    Area of Research

    Phase*

    Expand All Displaying 5 of 11

    COVID-19 (General)

    No trials are available at this time. Check back for updates.

    Fibrotic Diseases

    Nonalcoholic Steatohepatitis

    Area of Research

    Phase*

    BMS-986263
    HSP47 siRNA
    Area of Research: Compensated Cirrhosis From NASH
    Phase 2
    • View trial
      Save trial
    Clinical Trials For: BMS-986263, HSP47 siRNA in Compensated Cirrhosis From NASH
    • Safety and Effectiveness of BMS-986263 in Adults With Compensated Cirrhosis (Liver Disease) From Nonalcoholic Steatohepatitis (NASH)

      Recruiting, Phase 2

      NCT04267393
      NCT04267393
    Expand All Displaying 5 of 11

    Nonalcoholic Steatohepatitis

    No trials are available at this time. Check back for updates.

    Pulmonary Fibrosis

    Area of Research

    Phase*

    BMS-986278
    LPA1 Antagonist
    Area of Research: Pulmonary Fibrosis
    Phase 2
    • View trial
      Save trial
    Clinical Trials For: BMS-986278, LPA1 Antagonist in Pulmonary Fibrosis
    • A Study Measuring the Effectiveness, Safety, and Tolerability of BMS-986278 in Participants With Lung Fibrosis

      Recruiting, Phase 2

      NCT04308681
      NCT04308681
    Expand All Displaying 5 of 11

    Pulmonary Fibrosis

    No trials are available at this time. Check back for updates.

    Hematology

    Acute Lymphocytic Leukemia

    Area of Research

    Phase*

    Expand All Displaying 5 of 11

    Acute Lymphocytic Leukemia

    No trials are available at this time. Check back for updates.

    Acute Myeloid Leukemia

    Area of Research

    Phase*

    BMS-986397
    CK1a Degrader
    Area of Research: R/R AML
    Phase 1
    • View trial
      Save trial
    Clinical Trials For: BMS-986397, CK1a Degrader in R/R AML
    • Study to Evaluate Safety and Tolerability of CC-91633 (BMS-986397) in Participants With Relapsed or Refractory Acute Myeloid Leukemia or Relapsed or Refractory Higher-risk Myelodysplastic Syndromes

      Recruiting, Phase 1

      NCT04951778
      NCT04951778
    CC-96191
    NK Cell Engager
    Area of Research: R/R AML
    Phase 1
    • View trial
      Save trial
    Clinical Trials For: CC-96191, NK Cell Engager in R/R AML
    • Study of CC-96191 in Participants With Relapsed or Refractory Acute Myeloid Leukemia

      Recruiting, Phase 1

      NCT04789655
      NCT04789655
    Oral Azacitidine + BH3-mimetic
    DNA Methyltransferase Inhibitor + BH3-mimetic
    Area of Research: AML
    Phase 1
    • View trial
      Save trial
    Clinical Trials For: Oral Azacitidine + BH3-mimetic, DNA Methyltransferase Inhibitor + BH3-mimetic in AML
    • A Study to Assess Safety and Tolerability of CC-486 (ONUREG®, Oral Azacitidine) in Combination Therapy in Participants With Acute Myeloid Leukemia (AML)

      Recruiting, Phase 1

      NCT04887857
      NCT04887857
    Expand All Displaying 5 of 11

    Acute Myeloid Leukemia

    No trials are available at this time. Check back for updates.

    Beta-Thalassemia

    Area of Research

    Phase*

    Luspatercept-aamt
    Erythroid Maturation Agent
    Area of Research: Long-term Safety
    Phase 3
    • View trial
      Save trial
    Clinical Trials For: Luspatercept-aamt, Erythroid Maturation Agent in Long-term Safety
    • A Study to Evaluate Long-term Safety in Subjects Who Have Participated in Other Luspatercept (ACE-536) Clinical Trials

      Recruiting, Phase 3

      NCT04064060
      NCT04064060
    Expand All Displaying 5 of 11

    Beta-Thalassemia

    No trials are available at this time. Check back for updates.

    Chronic Lymphocytic Leukemia

    Area of Research

    Phase*

    Liso-cel ± BH3-mimetic
    CD-19 CAR T ± BH3-mimetic
    Area of Research: R/R CLL/SLL
    Phase 1/2
    • View trial
      Save trial
    Clinical Trials For: Liso-cel ± BH3-mimetic, CD-19 CAR T ± BH3-mimetic in R/R CLL/SLL
    • Study Evaluating Safety and Efficacy of JCAR017 in Subjects With Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL)

      Recruiting, Phase 1/2

      NCT03331198
      NCT03331198
    Liso-cel ± BTK Inhibitor
    CD-19 CAR T ± BTK Inhibitor
    Area of Research: R/R CLL/SLL
    Phase 1/2
    • View trial
      Save trial
    Clinical Trials For: Liso-cel ± BTK Inhibitor, CD-19 CAR T ± BTK Inhibitor in R/R CLL/SLL
    • Study Evaluating Safety and Efficacy of JCAR017 in Subjects With Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL)

      Recruiting, Phase 1/2

      NCT03331198
      NCT03331198
    Expand All Displaying 5 of 11

    Chronic Lymphocytic Leukemia

    No trials are available at this time. Check back for updates.

    Chronic Myelogenous Leukemia

    Area of Research

    Phase*

    Expand All Displaying 5 of 11

    Chronic Myelogenous Leukemia

    No trials are available at this time. Check back for updates.

    Hematologic Malignancies

    Area of Research

    Phase*

    CC-95251
    Anti-SIRPα
    Area of Research: Advanced Hematologic Cancers
    Phase 1
    • View trial
      Save trial
    Clinical Trials For: CC-95251, Anti-SIRPα in Advanced Hematologic Cancers
    • A Study of CC-95251, a Monoclonal Antibody Directed Against SIRPα, in Subjects With Advanced Solid and Hematologic Cancers

      Recruiting, Phase 1

      NCT03783403
      NCT03783403
    Nivolumab + Bempegaldesleukin
    Anti–PD-1 + CD-122-Preferential IL-2 Pathway Agonist
    Area of Research: Recurrent or
    Treatment-resistant
    Phase 1/2
    • View trial
      Save trial
    Clinical Trials For: Nivolumab + Bempegaldesleukin, Anti–PD-1 + CD-122-Preferential IL-2 Pathway Agonist in Recurrent or
    Treatment-resistant
    • A Study of Bempegaldesleukin (BEMPEG: NKTR-214) in Combination With Nivolumab in Children, Adolescents and Young Adults With Recurrent or Treatment-resistant Cancer

      Recruiting, Phase 1/2

      NCT04730349
      NCT04730349
    Expand All Displaying 5 of 11

    Hematologic Malignancies

    No trials are available at this time. Check back for updates.

    Lymphoma

    Area of Research

    Phase*

    CC-96673
    CD47xCD20
    Area of Research: R/R NHL
    Phase 1
    • View trial
      Save trial
    Clinical Trials For: CC-96673, CD47xCD20 in R/R NHL
    • A Dose Finding Study of CC-96673 in Participants With Relapsed or Refractory Non-Hodgkin's Lymphoma

      Recruiting, Phase 1

      NCT04860466
      NCT04860466
    CC-97540
    CD-19 NEX T
    Area of Research: DLBCL: 3L+
    Phase 1
    • View trial
      Save trial
    Clinical Trials For: CC-97540, CD-19 NEX T in DLBCL: 3L+
    • A Study of CC-97540, CD19-targeted NEX-T Chimeric Antigen Receptor (CAR) T Cells, in Subjects With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma

      Recruiting, Phase 1

      NCT04231747
      NCT04231747
    CC-99282 ± Anti–CD-19
    A/I Immunomodulatory Agent ± Anti–CD-19
    Area of Research: R/R NHL
    Phase 1
    • View trial
      Save trial
    Clinical Trials For: CC-99282 ± Anti–CD-19, A/I Immunomodulatory Agent ± Anti–CD-19 in R/R NHL
    • A Safety and Preliminary Efficacy Study of CC-99282, Alone and in Combination With Rituximab in Subjects With Relapsed or Refractory Non-hodgkin Lymphomas (R/R NHL)

      Recruiting, Phase 1

      NCT03930953
      NCT03930953
    CC-99282 ± Anti–CD-20
    A/I Immunomodulatory Agent ± Anti–CD-20
    Area of Research: R/R CLL/SLL
    Phase 1
    • View trial
      Save trial
    Clinical Trials For: CC-99282 ± Anti–CD-20, A/I Immunomodulatory Agent ± Anti–CD-20 in R/R CLL/SLL
    • A Safety and Preliminary Efficacy Study of CC-99282, Alone and in Combination With Rituximab in Subjects With Relapsed or Refractory Non-hodgkin Lymphomas (R/R NHL)

      Recruiting, Phase 1

      NCT03930953
      NCT03930953
    CC-99282 + Anti–CD-20
    A/I Immunomodulatory Agent + Anti–CD-20
    Area of Research: R/R NHL
    Phase 1
    • View trial
      Save trial
    Clinical Trials For: CC-99282 + Anti–CD-20, A/I Immunomodulatory Agent + Anti–CD-20 in R/R NHL
    • A Safety and Preliminary Efficacy Study of CC-99282 in Combination With Obinutuzumab in Subjects With Relapsed or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma

      Recruiting, Phase 1

      NCT04434196
      NCT04434196
    CC-99282 + Chemotherapy + Steroid
    A/I Immunomodulatory Agent + Chemotherapy + Steroid
    Area of Research: Aggressive B-cell Lymphoma
    Phase 1
    • View trial
      Save trial
    Clinical Trials For: CC-99282 + Chemotherapy + Steroid, A/I Immunomodulatory Agent + Chemotherapy + Steroid in Aggressive B-cell Lymphoma
    • Study of Safety and Efficacy of Iberdomide (CC-220) and CC-99282 Combined With R-CHOP to Treat Lymphoma

      Recruiting, Phase 1

      NCT04884035
      NCT04884035
    CC-99282 ± EZH2 Inhibitor
    A/I Immunomodulatory Agent ± EZH2 Inhibitor
    Area of Research: R/R NHL
    Phase 1
    • View trial
      Save trial
    Clinical Trials For: CC-99282 ± EZH2 Inhibitor, A/I Immunomodulatory Agent ± EZH2 Inhibitor in R/R NHL
    • A Safety and Preliminary Efficacy Study of CC-99282, Alone and in Combination With Rituximab in Subjects With Relapsed or Refractory Non-hodgkin Lymphomas (R/R NHL)

      Recruiting, Phase 1

      NCT03930953
      NCT03930953
    Iberdomide
    Immunomodulatory Agent
    Area of Research: R/R NHL: 3L+
    Phase 1
    • View trial
      Save trial
    Clinical Trials For: Iberdomide, Immunomodulatory Agent in R/R NHL: 3L+
    • A Dose Finding and Safety Study of CC-220, Alone and in Combination With an Anti-CD20 Monoclonal Antibody (mAb) in Subjects With Relapsed or Refractory Lymphomas

      Recruiting, Phase 1

      NCT04464798
      NCT04464798
    Iberdomide +
    Anti–CD-20
    Immunomodulatory Agent + Anti–CD-20
    Area of Research: NHL: 3L+
    Phase 1
    • View trial
      Save trial
    Clinical Trials For: Iberdomide +
    Anti–CD-20, Immunomodulatory Agent + Anti–CD-20 in NHL: 3L+
    • A Dose Finding and Safety Study of CC-220, Alone and in Combination With an Anti-CD20 Monoclonal Antibody (mAb) in Subjects With Relapsed or Refractory Lymphomas

      Recruiting, Phase 1

      NCT04464798
      NCT04464798
    Iberdomide +
    Anti–CD-20
    Immunomodulatory Agent + Anti–CD-20
    Area of Research: MCL: 3L+
    Phase 1
    • View trial
      Save trial
    Clinical Trials For: Iberdomide +
    Anti–CD-20, Immunomodulatory Agent + Anti–CD-20 in MCL: 3L+
    • A Dose Finding and Safety Study of CC-220, Alone and in Combination With an Anti-CD20 Monoclonal Antibody (mAb) in Subjects With Relapsed or Refractory Lymphomas

      Recruiting, Phase 1

      NCT04464798
      NCT04464798
    Iberdomide + Chemotherapy + Steroid
    Immunomodulatory Agent + Chemotherapy + Steroid
    Area of Research: Aggressive B-cell Lymphoma
    Phase 1
    • View trial
      Save trial
    Clinical Trials For: Iberdomide + Chemotherapy + Steroid, Immunomodulatory Agent + Chemotherapy + Steroid in Aggressive B-cell Lymphoma
    • Study of Safety and Efficacy of Iberdomide (CC-220) and CC-99282 Combined With R-CHOP to Treat Lymphoma

      Recruiting, Phase 1

      NCT04884035
      NCT04884035
    Liso-cel
    CD-19 CAR T
    Area of Research: MCL: 3L+
    Phase 1
    • View trial
      Save trial
    Clinical Trials For: Liso-cel, CD-19 CAR T in MCL: 3L+
    • Study Evaluating the Safety and Pharmacokinetics of JCAR017 in B-cell Non-Hodgkin Lymphoma (TRANSCEND-NHL-001)

      Recruiting, Phase 1

      NCT02631044
      NCT02631044
    Liso-cel + Anti–PD-1
    CD-19 CAR T + Anti–PD-1
    Area of Research: DLBCL: 3L
    Phase 1/2
    • View trial
      Save trial
    Clinical Trials For: Liso-cel + Anti–PD-1, CD-19 CAR T + Anti–PD-1 in DLBCL: 3L
    • A Safety and Efficacy Trial of JCAR017 Combinations in Subjects With Relapsed/Refractory B-cell Malignancies (PLATFORM)

      Recruiting, Phase 1/2

      NCT03310619
      NCT03310619
    Liso-cel + BTK Inhibitor
    CD-19 CAR T + BTK Inhibitor
    Area of Research: DLBCL: 3L
    Phase 1/2
    • View trial
      Save trial
    Clinical Trials For: Liso-cel + BTK Inhibitor, CD-19 CAR T + BTK Inhibitor in DLBCL: 3L
    • A Safety and Efficacy Trial of JCAR017 Combinations in Subjects With Relapsed/Refractory B-cell Malignancies (PLATFORM)

      Recruiting, Phase 1/2

      NCT03310619
      NCT03310619
    Liso-cel + CC-99282
    CD-19 CAR T + A/I Immunomodulatory Agent
    Area of Research: DLBCL: 3L
    Phase 1/2
    • View trial
      Save trial
    Clinical Trials For: Liso-cel + CC-99282, CD-19 CAR T + A/I Immunomodulatory Agent in DLBCL: 3L
    • A Safety and Efficacy Trial of JCAR017 Combinations in Subjects With Relapsed/Refractory B-cell Malignancies (PLATFORM)

      Recruiting, Phase 1/2

      NCT03310619
      NCT03310619
    Liso-cel + Chemotherapy
    CD-19 CAR T + Chemo
    Area of Research: Pediatric R/R B-ALL and B-NHL
    Phase 1/2
    • View trial
      Save trial
    Clinical Trials For: Liso-cel + Chemotherapy, CD-19 CAR T + Chemo in Pediatric R/R B-ALL and B-NHL
    • A Study to Evaluate the Safety and Efficacy of JCAR017 in Pediatric Subjects With Relapsed/Refractory (r/r) B-cell Acute Lymphoblastic Leukemia (B-ALL) and B-cell Non-Hodgkin Lymphoma (B-NHL)

      Recruiting, Phase 1/2

      NCT03743246
      NCT03743246
    Liso-cel + Chemotherapy
    CD-19 CAR T
    Area of Research: FL/MZL: 2L+/ 3L+
    Phase 2
    • View trial
      Save trial
    Clinical Trials For: Liso-cel + Chemotherapy, CD-19 CAR T in FL/MZL: 2L+/ 3L+
    • A Study to Evaluate the Efficacy and Safety of JCAR017 in Adult Subjects With Relapsed or Refractory Indolent B-cell Non-Hodgkin Lymphoma (NHL)

      Recruiting, Phase 2

      NCT04245839
      NCT04245839
    Liso-cel + Iberdomide
    CD-19 CAR T + Immunomodulatory Agent
    Area of Research: DLBCL: 3L
    Phase 1/2
    • View trial
      Save trial
    Clinical Trials For: Liso-cel + Iberdomide, CD-19 CAR T + Immunomodulatory Agent in DLBCL: 3L
    • A Safety and Efficacy Trial of JCAR017 Combinations in Subjects With Relapsed/Refractory B-cell Malignancies (PLATFORM)

      Recruiting, Phase 1/2

      NCT03310619
      NCT03310619
    Liso-cel + Relatlimab ± Nivolumab
    CD-19 CAR T + Anti–LAG-3 ± Anti–PD-1
    Area of Research: B-cell Lymphomas
    Phase 1/2
    • View trial
      Save trial
    Clinical Trials For: Liso-cel + Relatlimab ± Nivolumab, CD-19 CAR T + Anti–LAG-3 ± Anti–PD-1 in B-cell Lymphomas
    • A Safety and Efficacy Trial of JCAR017 Combinations in Subjects With Relapsed/Refractory B-cell Malignancies (PLATFORM)

      Recruiting, Phase 1/2

      NCT03310619
      NCT03310619
    TRPH-222
    CD22 ADC
    Area of Research: R/R Lymphoma
    Phase 1
    • View trial
      Save trial
    Clinical Trials For: TRPH-222, CD22 ADC in R/R Lymphoma
    • Study of TRPH-222 in Patients With Relapsed and/or Refractory B-cell Lymphoma

      Recruiting, Phase 1

      NCT03682796
      NCT03682796
    Expand All Displaying 5 of 11

    Lymphoma

    No trials are available at this time. Check back for updates.

    Multiple Myeloma

    Area of Research

    Phase*

    BMS-986405
    BCMA ADC ± GSI
    Area of Research: R/R MM: 4L+
    Phase 1
    • View trial
      Save trial
    Clinical Trials For: BMS-986405, BCMA ADC ± GSI in R/R MM: 4L+
    • A Study of CC-99712, a BCMA Antibody-drug Conjugate, in Participants With Relapsed and Refractory Multiple Myeloma

      Recruiting, Phase 1

      NCT04036461
      NCT04036461
    CC-92328
    BCMA NK Cell Engager
    Area of Research: R/R MM
    Phase 1
    • View trial
      Save trial
    Clinical Trials For: CC-92328, BCMA NK Cell Engager in R/R MM
    • Study to Evaluate the Safety and Tolerability of CC-92328 in Participants With Relapsed and/or Refractory Multiple Myeloma

      Recruiting, Phase 1

      NCT04975399
      NCT04975399
    CC-92480 + Anti–CD-38 + Dexamethasone
    A/I Immunomodulatory Agent + Anti–CD-38 + Steroid
    Area of Research: R/R MM and NDMM
    Phase 1/2
    • View trial
      Save trial
    Clinical Trials For: CC-92480 + Anti–CD-38 + Dexamethasone, A/I Immunomodulatory Agent + Anti–CD-38 + Steroid in R/R MM and NDMM
    • A Study to Determine the Recommended Dose and Regimen and Evaluate the Safety and Preliminary Efficacy of CC-92480 in Combination With Standard Treatments in Subjects With Relapsed or Refractory Multiple Myeloma (RRMM) and Newly Diagnosed Multiple Myeloma (NDMM)

      Recruiting, Phase 1/2

      NCT03989414
      NCT03989414
    CC-92480 + Anti-SLAMF7 + Dexamethasone
    A/I Immunomodulatory Agent + Anti-SLAMF7 + Steroid
    Area of Research: R/R MM and NDMM
    Phase 1/2
    • View trial
      Save trial
    Clinical Trials For: CC-92480 + Anti-SLAMF7 + Dexamethasone, A/I Immunomodulatory Agent + Anti-SLAMF7 + Steroid in R/R MM and NDMM
    • A Study to Determine the Recommended Dose and Regimen and Evaluate the Safety and Preliminary Efficacy of CC-92480 in Combination With Standard Treatments in Subjects With Relapsed or Refractory Multiple Myeloma (RRMM) and Newly Diagnosed Multiple Myeloma (NDMM)

      Recruiting, Phase 1/2

      NCT03989414
      NCT03989414
    CC-92480 ± Dexamethasone
    A/I Immunomodulatory Agent ± Steroid
    Area of Research: R/R MM
    Phase 1/2
    • View trial
      Save trial
    Clinical Trials For: CC-92480 ± Dexamethasone, A/I Immunomodulatory Agent ± Steroid in R/R MM
    • A Safety, PK and Efficacy Study of CC-92480 Monotherapy and in Combination With Dexamethasone in Subjects With Relapsed and Refractory Multiple Myeloma (RRMM)

      Recruiting, Phase 1/2

      NCT03374085
      NCT03374085
    CC-92480 + Proteasome Inhibitor + Dexamethasone
    A/I Immunomodulatory Agent + Proteasome Inhibitor + Steroid
    Area of Research: R/R MM and NDMM
    Phase 1/2
    • View trial
      Save trial
    Clinical Trials For: CC-92480 + Proteasome Inhibitor + Dexamethasone, A/I Immunomodulatory Agent + Proteasome Inhibitor + Steroid in R/R MM and NDMM
    • A Study to Determine the Recommended Dose and Regimen and Evaluate the Safety and Preliminary Efficacy of CC-92480 in Combination With Standard Treatments in Subjects With Relapsed or Refractory Multiple Myeloma (RRMM) and Newly Diagnosed Multiple Myeloma (NDMM)

      Recruiting, Phase 1/2

      NCT03989414
      NCT03989414
    CC-93269
    BCMA TCE
    Area of Research: R/R MM
    Phase 1
    • View trial
      Save trial
    Clinical Trials For: CC-93269, BCMA TCE in R/R MM
    • Study of CC-93269, a BCMA x CD3 T Cell Engaging Antibody, in Subjects With Relapsed and Refractory Multiple Myeloma

      Recruiting, Phase 1

      NCT03486067
      NCT03486067
    CC-95266
    GPRC5D CAR T
    Area of Research: R/R MM: 4L+
    Phase 1
    • View trial
      Save trial
    Clinical Trials For: CC-95266, GPRC5D CAR T in R/R MM: 4L+
    • A Study of CC-95266 in Subjects With Relapsed and/or Refractory Multiple Myeloma

      Recruiting, Phase 1

      NCT04674813
      NCT04674813
    CC-98633
    BCMA NEX T
    Area of Research: R/R MM: 4L+
    Phase 1
    • View trial
      Save trial
    Clinical Trials For: CC-98633, BCMA NEX T in R/R MM: 4L+
    • A Study of CC-98633, BCMA-targeted Chimeric Antigen Receptor (CAR) T Cells, in Subjects With Relapsed and/or Refractory Multiple Myeloma

      Recruiting, Phase 1

      NCT04394650
      NCT04394650
    Iberdomide +
    Anti–CD-38 + Dexamethasone
    Immunomodulatory Agent + Anti–CD-38 + Steroid
    Area of Research: R/R MM: 3L+
    Phase 3
    • View trial
      Save trial
    Clinical Trials For: Iberdomide +
    Anti–CD-38 + Dexamethasone, Immunomodulatory Agent + Anti–CD-38 + Steroid in R/R MM: 3L+
    • Open-label Study Comparing Iberdomide, Daratumumab and Dexamethasone (IberDd) Versus Daratumumab, Bortezomib, and Dexamethasone (DVd) in Participants With Relapsed or Refractory Multiple Myeloma (RRMM)

      Not Yet Recruiting, Phase 3

      NCT04975997
      NCT04975997
    Iberdomide ± Dexamethasone
    Immunomodulatory Agent ± Steroid
    Area of Research: R/R MM
    Phase 1/2
    • View trial
      Save trial
    Clinical Trials For: Iberdomide ± Dexamethasone, Immunomodulatory Agent ± Steroid in R/R MM
    • A Study to Determine Dose, Safety, Tolerability and Efficacy of CC-220 Monotherapy, and in Combination With Other Treatments in Subjects With Multiple Myeloma

      Recruiting, Phase 1/2

      NCT02773030
      NCT02773030
    Iberdomide + Dexamethasone +
    Anti–CD-38
    Immunomodulatory Agent + Steroid +
    Anti–CD-38
    Area of Research: R/R MM
    Phase 1/2
    • View trial
      Save trial
    Clinical Trials For: Iberdomide + Dexamethasone +
    Anti–CD-38, Immunomodulatory Agent + Steroid +
    Anti–CD-38 in R/R MM
    • A Study to Determine Dose, Safety, Tolerability and Efficacy of CC-220 Monotherapy, and in Combination With Other Treatments in Subjects With Multiple Myeloma

      Recruiting, Phase 1/2

      NCT02773030
      NCT02773030
    Iberdomide + Dexamethasone + Proteasome Inhibitor
    Immunomodulatory Agent + Steroid + Proteasome Inhibitor
    Area of Research: NDMM
    Phase 1/2
    • View trial
      Save trial
    Clinical Trials For: Iberdomide + Dexamethasone + Proteasome Inhibitor, Immunomodulatory Agent + Steroid + Proteasome Inhibitor in NDMM
    • A Study to Determine Dose, Safety, Tolerability and Efficacy of CC-220 Monotherapy, and in Combination With Other Treatments in Subjects With Multiple Myeloma

      Recruiting, Phase 1/2

      NCT02773030
      NCT02773030
    Ide-cel
    BCMA CAR T
    Area of Research: R/R MM: 3L-4L
    Phase 3
    • View trial
      Save trial
    Clinical Trials For: Ide-cel, BCMA CAR T in R/R MM: 3L-4L
    • Efficacy and Safety Study of bb2121 Versus Standard Regimens in Subjects With Relapsed and Refractory Multiple Myeloma (RRMM)

      Recruiting, Phase 3

      NCT03651128
      NCT03651128
    Ide-cel
    BCMA CAR T
    Area of Research: R/R MM
    Phase 2
    • View trial
      Save trial
    Clinical Trials For: Ide-cel, BCMA CAR T in R/R MM
    • An Efficacy and Safety Study of bb2121 in Subjects With Relapsed and Refractory Multiple Myeloma and in Subjects With High-risk Multiple Myeloma

      Recruiting, Phase 2

      NCT03601078
      NCT03601078
    Ide-cel + BMS-986405
    BCMA CAR T + GSI
    Area of Research: R/R MM
    Phase 1/2
    • View trial
      Save trial
    Clinical Trials For: Ide-cel + BMS-986405, BCMA CAR T + GSI in R/R MM
    • Safety and Efficacy of bb2121 (Ide-cel) Combinations in Multiple Myeloma

      Recruiting, Phase 1/2

      NCT04855136
      NCT04855136
    Ide-cel + Iberdomide ± Dexamethasone
    BCMA CAR T + Immunomodulatory Agent ± Steroid
    Area of Research: R/R MM
    Phase 1/2
    • View trial
      Save trial
    Clinical Trials For: Ide-cel + Iberdomide ± Dexamethasone, BCMA CAR T + Immunomodulatory Agent ± Steroid in R/R MM
    • Safety and Efficacy of bb2121 (Ide-cel) Combinations in Multiple Myeloma

      Recruiting, Phase 1/2

      NCT04855136
      NCT04855136
    Ide-cel + Pomalidomide + Proteasome Inhibitor + Dexamethasone
    BCMA CAR T + Immunomodulatory Agent + Proteasome Inhibitor + Steroid
    Area of Research: R/R MM
    Phase 1/2
    • View trial
      Save trial
    Clinical Trials For: Ide-cel + Pomalidomide + Proteasome Inhibitor + Dexamethasone, BCMA CAR T + Immunomodulatory Agent + Proteasome Inhibitor + Steroid in R/R MM
    • Safety and Efficacy of bb2121 (Ide-cel) Combinations in Multiple Myeloma

      Recruiting, Phase 1/2

      NCT04855136
      NCT04855136
    Ide-cel + Pomalidomide
    + Anti–CD-38 + Dexamethasone
    BCMA CAR T + Immunomodulatory Agent + Anti–CD-38 + Steroid
    Area of Research: R/R MM
    Phase 1/2
    • View trial
      Save trial
    Clinical Trials For: Ide-cel + Pomalidomide
    + Anti–CD-38 + Dexamethasone, BCMA CAR T + Immunomodulatory Agent + Anti–CD-38 + Steroid in R/R MM
    • Safety and Efficacy of bb2121 (Ide-cel) Combinations in Multiple Myeloma

      Recruiting, Phase 1/2

      NCT04855136
      NCT04855136
    Expand All Displaying 5 of 11

    Multiple Myeloma

    No trials are available at this time. Check back for updates.

    Myelodysplastic Syndromes

    Area of Research

    Phase*

    BMS-986397
    CK1α Degrader
    Area of Research: R/R HR-MDS
    Phase 1
    • View trial
      Save trial
    Clinical Trials For: BMS-986397, CK1α Degrader in R/R HR-MDS
    • Study to Evaluate Safety and Tolerability of CC-91633 (BMS-986397) in Participants With Relapsed or Refractory Acute Myeloid Leukemia or Relapsed or Refractory Higher-risk Myelodysplastic Syndromes

      Recruiting, Phase 1

      NCT04951778
      NCT04951778
    Luspatercept-aamt
    Erythroid Maturation Agent
    Area of Research: Anemia Due to MDS; ESA-naïve
    Phase 3
    • View trial
      Save trial
    Clinical Trials For: Luspatercept-aamt, Erythroid Maturation Agent in Anemia Due to MDS; ESA-naïve
    • Efficacy and Safety Study of Luspatercept (ACE-536) Versus Epoetin Alfa for the Treatment of Anemia Due to IPSS-R Very Low, Low or Intermediate Risk Myelodysplastic Syndromes (MDS) in ESA Naļve Subjects Who Require Red Blood Cell Transfusions

      Recruiting, Phase 3

      NCT03682536
      NCT03682536
    Luspatercept-aamt
    Erythroid Maturation Agent
    Area of Research: Anemia Due to MDS
    Phase 2
    • View trial
      Save trial
    Clinical Trials For: Luspatercept-aamt, Erythroid Maturation Agent in Anemia Due to MDS
    • An Efficacy and Safety Study of Luspatercept (ACE-536) for the Treatment of Anemia Due to IPSS-R Very Low, Low or Intermediate Risk Myelodysplastic Syndromes (MDS) in Japanese Subjects Who Are Not Requiring Red Blood Cell Transfusion

      Recruiting, Phase 2

      NCT03900715
      NCT03900715
    Luspatercept-aamt
    Erythroid Maturation Agent
    Area of Research: Long-term Safety
    Phase 3
    • View trial
      Save trial
    Clinical Trials For: Luspatercept-aamt, Erythroid Maturation Agent in Long-term Safety
    • A Study to Evaluate Long-term Safety in Subjects Who Have Participated in Other Luspatercept (ACE-536) Clinical Trials

      Recruiting, Phase 3

      NCT04064060
      NCT04064060
    Luspatercept-aamt
    Erythroid Maturation Agent
    Area of Research: Anemia Due to Transfusion-dependent MDS-RS
    Phase 2
    • View trial
      Save trial
    Clinical Trials For: Luspatercept-aamt, Erythroid Maturation Agent in Anemia Due to Transfusion-dependent MDS-RS
    • A Study to Evaluate the Efficacy, Pharmacokinetics and Safety of Luspatercept (ACE-536) for the Treatment of Anemia Due to IPSS-R Very Low, Low, or Intermediate Risk Myelodysplastic Syndromes (MDS) in Chinese and Japanese Subjects With Ring Sideroblasts Who Require Red Blood Cell Transfusions

      Recruiting, Phase 2

      NCT04477850
      NCT04477850
    Expand All Displaying 5 of 11

    Myelodysplastic Syndromes

    No trials are available at this time. Check back for updates.

    Myelofibrosis

    Area of Research

    Phase*

    BMS-986158 ± Fedratinib
    BETi ± JAK2 Inhibitor
    Area of Research: DIPSS–intermediate- or High-risk Myelofibrosis
    Phase 1
    • View trial
      Save trial
    Clinical Trials For: BMS-986158 ± Fedratinib, BETi ± JAK2 Inhibitor in DIPSS–intermediate- or High-risk Myelofibrosis
    • A Study to Assess the Safety and Tolerability of BMS-986158 Alone and in Combination With Either Ruxolitinib or Fedratinib in Participants With Blood Cancer (Myelofibrosis)

      Recruiting, Phase 1

      NCT04817007
      NCT04817007
    BMS-986158 ± JAK Inhibitor
    BETi ± JAK Inhibitor
    Area of Research: DIPSS–intermediate- or High-risk Myelofibrosis
    Phase 1
    • View trial
      Save trial
    Clinical Trials For: BMS-986158 ± JAK Inhibitor, BETi ± JAK Inhibitor in DIPSS–intermediate- or High-risk Myelofibrosis
    • A Study to Assess the Safety and Tolerability of BMS-986158 Alone and in Combination With Either Ruxolitinib or Fedratinib in Participants With Blood Cancer (Myelofibrosis)

      Recruiting, Phase 1

      NCT04817007
      NCT04817007
    Fedratinib
    JAK2 Inhibitor
    Area of Research: PMF, Post-PV MF,
    Post-ET MF
    Phase 3
    Phase 1/2
    • 1 trial
    • 1 trial
    • View trials
      Save trials
    Clinical Trials For: Fedratinib, JAK2 Inhibitor in PMF, Post-PV MF,
    Post-ET MF
    • An Efficacy and Safety Study of Fedratinib Compared to Best Available Therapy in Subjects With DIPSS-intermediate or High-risk Primary Myelofibrosis, Post-polycythemia Vera Myelofibrosis, or Post-essential Thrombocythemia Myelofibrosis and Previously Treated With Ruxolitinib

      Recruiting, Phase 3

      NCT03952039
      NCT03952039
    • A Study of Fedratinib in Japanese Subjects With DIPSS (Dynamic International Prognostic Scoring System)- Intermediate or High-risk Primary Myelofibrosis (PMF), Post-polycythemia Vera Myelofibrosis (Post-PV MF), or Post-essential Thrombocythemia Myelofibrosis (Post-ET MF)

      Recruiting, Phase 1/2

      NCT04446650
      NCT04446650
    Luspatercept-aamt
    Erythroid Maturation Agent
    Area of Research: Long-term Safety
    Phase 3
    • View trial
      Save trial
    Clinical Trials For: Luspatercept-aamt, Erythroid Maturation Agent in Long-term Safety
    • A Study to Evaluate Long-term Safety in Subjects Who Have Participated in Other Luspatercept (ACE-536) Clinical Trials

      Recruiting, Phase 3

      NCT04064060
      NCT04064060
    Luspatercept-aamt
    Erythroid Maturation Agent
    Area of Research: MPN-associated MF
    Phase 3
    • View trial
      Save trial
    Clinical Trials For: Luspatercept-aamt, Erythroid Maturation Agent in MPN-associated MF
    • An Efficacy and Safety Study of Luspatercept (ACE-536) Versus Placebo in Subjects With Myeloproliferative Neoplasm-associated Myelofibrosis on Concomitant JAK2 Inhibitor Therapy and Who Require Red Blood Cell Transfusions

      Recruiting, Phase 3

      NCT04717414
      NCT04717414
    Expand All Displaying 5 of 11

    Myelofibrosis

    No trials are available at this time. Check back for updates.

    Immunology

    Ankylosing Spondylitis

    Area of Research

    Phase*

    CC-99677
    MK2i
    Area of Research: Active AS, SpA, axSpA
    Phase 2
    • View trial
      Save trial
    Clinical Trials For: CC-99677, MK2i in Active AS, SpA, axSpA
    • A Study of CC-99677 in Participants With Active Ankylosing Spondylitis

      Recruiting, Phase 2

      NCT04947579
      NCT04947579
    Expand All Displaying 5 of 11

    Ankylosing Spondylitis

    No trials are available at this time. Check back for updates.

    Atopic Dermatitis

    Area of Research

    Phase*

    BMS-986166
    S1P1R Modulator
    Area of Research: Moderate to Severe Atopic Dermatitis
    Phase 2
    • View trial
      Save trial
    Clinical Trials For: BMS-986166, S1P1R Modulator in Moderate to Severe Atopic Dermatitis
    • A Study of BMS-986166 or Branebrutinib for the Treatment of Participants With Atopic Dermatitis

      Recruiting, Phase 2

      NCT05014438
      NCT05014438
    Branebrutinib
    BTK Inhibitor
    Area of Research: Moderate to Severe Atopic Dermatitis
    Phase 2
    • View trial
      Save trial
    Clinical Trials For: Branebrutinib, BTK Inhibitor in Moderate to Severe Atopic Dermatitis
    • A Study of BMS-986166 or Branebrutinib for the Treatment of Participants With Atopic Dermatitis

      Recruiting, Phase 2

      NCT05014438
      NCT05014438
    Cendakimab
    Anti–IL-13
    Area of Research: Moderate to Severe Atopic Dermatitis
    Phase 2
    • View trial
      Save trial
    Clinical Trials For: Cendakimab, Anti–IL-13 in Moderate to Severe Atopic Dermatitis
    • A Study to Evaluate Safety and Effectiveness of Cendakimab (CC-93538) in Participants With Moderate to Severe Atopic Dermatitis

      Recruiting, Phase 2

      NCT04800315
      NCT04800315
    Expand All Displaying 5 of 11

    Atopic Dermatitis

    No trials are available at this time. Check back for updates.

    Autoimmune Disease

    Area of Research

    Phase*

    Expand All Displaying 5 of 11

    Autoimmune Disease

    No trials are available at this time. Check back for updates.

    Crohn’s Disease

    Area of Research

    Phase*

    Deucravacitinib
    TYK2i
    Area of Research: Moderate to Severe Crohn's Disease
    Phase 2
    • View trial
      Save trial
    Clinical Trials For: Deucravacitinib, TYK2i in Moderate to Severe Crohn's Disease
    • A Study to Evaluate the Long-term Safety and Efficacy of BMS-986165 in Participants With Crohn's Disease or Ulcerative Colitis

      Recruiting, Phase 2

      NCT04877990
      NCT04877990
    Deucravacitinib
    TYK2i
    Area of Research: Crohn's Disease
    Phase 2
    • View trial
      Save trial
    Clinical Trials For: Deucravacitinib, TYK2i in Crohn's Disease
    • An Investigational Study of Experimental Medication BMS-986165 in Participants With Moderate to Severe Crohn's Disease

      Recruiting, Phase 2

      NCT03599622
      NCT03599622
    Ozanimod
    S1P1R Modulator
    Area of Research: Crohn's Disease
    Phase 3
    • View trials
      Save trials
    Clinical Trials For: Ozanimod, S1P1R Modulator in Crohn's Disease
    • A Placebo-controlled Study of Oral Ozanimod as Maintenance Therapy for Moderately to Severely Active Crohn's Disease

      Recruiting, Phase 3

      NCT03464097
      NCT03464097
    • An Extension Study of Oral Ozanimod for Moderately to Severely Active Crohn's Disease

      Recruiting, Phase 3

      NCT03467958
      NCT03467958
    • Induction Study #1 of Oral Ozanimod as Induction Therapy for Moderately to Severely Active Crohn's Disease

      Recruiting, Phase 3

      NCT03440372
      NCT03440372
    • Induction Study #2 of Oral Ozanimod as Induction Therapy for Moderately to Severely Active Crohn's Disease

      Recruiting, Phase 3

      NCT03440385
      NCT03440385
    Expand All Displaying 5 of 11

    Crohn’s Disease

    No trials are available at this time. Check back for updates.

    Cutaneous Lupus Erythematosus

    Area of Research

    Phase*

    Afimetoran
    TLR 7/8 Inhibitor
    Area of Research: Lupus Erythematosus
    Phase 1
    • View trial
      Save trial
    Clinical Trials For: Afimetoran, TLR 7/8 Inhibitor in Lupus Erythematosus
    • A Study to Assess the Safety and Drug Levels of BMS-986256 in Participants With Active Cutaneous Lupus Erythematosus

      Recruiting, Phase 1

      NCT04493541
      NCT04493541
    Deucravacitinib
    TYK2i
    Area of Research: Active DLE and/or SCLE
    Phase 2
    • View trial
      Save trial
    Clinical Trials For: Deucravacitinib, TYK2i in Active DLE and/or SCLE
    • A Study to Evaluate Efficacy and Safety of BMS-986165 in Participants With Active Discoid and/or Subacute Cutaneous Lupus Erythematosus (DLE/SCLE)

      Recruiting, Phase 2

      NCT04857034
      NCT04857034
    Expand All Displaying 5 of 11

    Cutaneous Lupus Erythematosus

    No trials are available at this time. Check back for updates.

    Eosinophilic Esophagitis

    Area of Research

    Phase*

    Cendakimab
    Anti–IL-13
    Area of Research: Eosinophilic Esophagitis
    Phase 3
    • View trial
      Save trial
    Clinical Trials For: Cendakimab, Anti–IL-13 in Eosinophilic Esophagitis
    • A Study to Evaluate the Efficacy and Safety of CC-93538 in Adult and Adolescent Participants With Eosinophilic Esophagitis

      Recruiting, Phase 3

      NCT04753697
      NCT04753697
    Cendakimab
    Anti–IL-13
    Area of Research: Active Eosinophilic Esophagitis
    Phase 3
    • View trial
      Save trial
    Clinical Trials For: Cendakimab, Anti–IL-13 in Active Eosinophilic Esophagitis
    • Safety Study of CC-93538 in Adult and Adolescent Participants With Eosinophilic Esophagitis

      Recruiting, Phase 3

      NCT04991935
      NCT04991935
    Expand All Displaying 5 of 11

    Eosinophilic Esophagitis

    No trials are available at this time. Check back for updates.

    Idiopathic Inflammatory Myopathy

    Area of Research

    Phase*

    Expand All Displaying 5 of 11

    Idiopathic Inflammatory Myopathy

    No trials are available at this time. Check back for updates.

    Lupus Nephritis

    Area of Research

    Phase*

    Expand All Displaying 5 of 11

    Lupus Nephritis

    No trials are available at this time. Check back for updates.

    Multiple Sclerosis

    Area of Research

    Phase*

    BMS-986196
    —
    Area of Research: Multiple Sclerosis
    Phase 1
    • View trial
      Save trial
    Clinical Trials For: BMS-986196, — in Multiple Sclerosis
    • A Study to Evaluate the Safety, Tolerability, Kinetics, Biodistribution and Repeatability of 11C-BMS-986196 After Intravenous (IV) Administration in Healthy Participants and After Repeat IV Administration in Participants With Multiple Sclerosis

      Not Yet Recruiting, Phase 1

      NCT05064436
      NCT05064436
    Ozanimod
    S1P1R Modulator
    Area of Research: Multiple Sclerosis
    Phase 3
    • View trial
      Save trial
    Clinical Trials For: Ozanimod, S1P1R Modulator in Multiple Sclerosis
    • Study Describing Cognitive Processing Speed Changes in Relapsing Multiple Sclerosis Subjects Treated With Ozanimod (RPC-1063)

      Recruiting, Phase 3

      NCT04140305
      NCT04140305
    Ozanimod
    S1P1R Modulator
    Area of Research: Multiple Sclerosis
    Phase 3
    • View trial
      Save trial
    Clinical Trials For: Ozanimod, S1P1R Modulator in Multiple Sclerosis
    • Safety Study to Evaluate Immune Response of Vaccines in Participants With Relapsing Forms of Multiple Sclerosis Who Receive Ozanimod Compared to Non-Pegylated Interferon (IFN)-β or No Disease Modifying Therapy

      Recruiting, Phase 3

      NCT05028634
      NCT05028634
    Expand All Displaying 5 of 11

    Multiple Sclerosis

    No trials are available at this time. Check back for updates.

    Psoriasis

    Area of Research

    Phase*

    Deucravacitinib
    TYK2i
    Area of Research: Moderate to Severe Plaque Psoriasis
    Phase 3
    • View trial
      Save trial
    Clinical Trials For: Deucravacitinib, TYK2i in Moderate to Severe Plaque Psoriasis
    • A Study to Evaluate the Drug Levels, Efficacy and Safety of BMS-986165 in Adolescent Participants With Moderate to Severe Plaque Psoriasis

      Recruiting, Phase 3

      NCT04772079
      NCT04772079
    Expand All Displaying 5 of 11

    Psoriasis

    No trials are available at this time. Check back for updates.

    Psoriatic Arthritis

    Area of Research

    Phase*

    Deucravacitinib
    TYK2i
    Area of Research: Active PsA, Naïve to Biologic DMARDs or Previously Received Treatment With TNFα Inhibitor
    Phase 3
    • View trial
      Save trial
    Clinical Trials For: Deucravacitinib, TYK2i in Active PsA, Naïve to Biologic DMARDs or Previously Received Treatment With TNFα Inhibitor
    • A Study to Determine the Efficacy and Safety of Deucravacitinib Compared With Placebo in Participants With Active Psoriatic Arthritis (PsA) Who Are Naļve to Biologic Disease Modifying Anti-rheumatic Drugs or Had Previously Received TNFα Inhibitor Treatment

      Recruiting, Phase 3

      NCT04908189
      NCT04908189
    Deucravacitinib
    TYK2i
    Area of Research: Active PsA, Naïve to Biologic DMARDs
    Phase 3
    • View trial
      Save trial
    Clinical Trials For: Deucravacitinib, TYK2i in Active PsA, Naïve to Biologic DMARDs
    • A Study to Determine the Efficacy and Safety of Deucravacitinib Compared With Placebo in Participants With Active Psoriatic Arthritis (PsA) Who Are Naļve to Biologic Disease-modifying Anti-rheumatic Drugs

      Recruiting, Phase 3

      NCT04908202
      NCT04908202
    Expand All Displaying 5 of 11

    Psoriatic Arthritis

    No trials are available at this time. Check back for updates.

    Renal Allograft

    Area of Research

    Phase*

    Belatacept + Immunosuppression
    Immunomodulatory Agent
    Area of Research: Adolescent Renal Allograft Recipients
    Phase 3
    • View trial
      Save trial
    Clinical Trials For: Belatacept + Immunosuppression, Immunomodulatory Agent in Adolescent Renal Allograft Recipients
    • A Study to Evaluate the Benefits and Risks of Conversion of Existing Adolescent Kidney Transplant Recipients Aged 12 to <18 Years to a Belatacept-based Immunosuppressive Regimen as Compared to Continuation of a Calcineurin Inhibitor-based Regimen, and Their Adherence to Immunosuppressive Medications

      Recruiting, Phase 3

      NCT04877288
      NCT04877288
    Expand All Displaying 5 of 11

    Renal Allograft

    No trials are available at this time. Check back for updates.

    Renal Transplant

    Area of Research

    Phase*

    Expand All Displaying 5 of 11

    Renal Transplant

    No trials are available at this time. Check back for updates.

    Rheumatoid Arthritis

    Area of Research

    Phase*

    Abatacept + DMARD
    Immunomodulatory Agent
    Area of Research: Early, Seropositive RA
    Phase 3
    • View trial
      Save trial
    Clinical Trials For: Abatacept + DMARD, Immunomodulatory Agent in Early, Seropositive RA
    • A Study to Compare the Response to Treatment With Abatacept vs Adalimumab, on Background Methotrexate, in Adults With Early, Seropositive, and Shared Epitope-positive Rheumatoid Arthritis and an Inadequate Response to Methotrexate

      Recruiting, Phase 3

      NCT04909801
      NCT04909801
    Branebrutinib + Abatacept
    BTK Inhibitor + Immunomodulatory Agent
    Area of Research: Rheumatoid Arthritis
    Phase 2
    • View trial
      Save trial
    Clinical Trials For: Branebrutinib + Abatacept, BTK Inhibitor + Immunomodulatory Agent in Rheumatoid Arthritis
    • Study to Assess Safety and Effectiveness of Branebrutinib Treatment in Participants With Active Systemic Lupus Erythematosus or Primary Sjögren's Syndrome, or Branebrutinib Treatment Followed by Open-label Abatacept Treatment in Study Participants With Active Rheumatoid Arthritis

      Recruiting, Phase 2

      NCT04186871
      NCT04186871
    Expand All Displaying 5 of 11

    Rheumatoid Arthritis

    No trials are available at this time. Check back for updates.

    Sjögren Syndrome

    Area of Research

    Phase*

    Branebrutinib
    BTK Inhibitor
    Area of Research: Sjögren Syndrome
    Phase 2
    • View trial
      Save trial
    Clinical Trials For: Branebrutinib, BTK Inhibitor in Sjögren Syndrome
    • Study to Assess Safety and Effectiveness of Branebrutinib Treatment in Participants With Active Systemic Lupus Erythematosus or Primary Sjögren's Syndrome, or Branebrutinib Treatment Followed by Open-label Abatacept Treatment in Study Participants With Active Rheumatoid Arthritis

      Recruiting, Phase 2

      NCT04186871
      NCT04186871
    Expand All Displaying 5 of 11

    Sjögren Syndrome

    No trials are available at this time. Check back for updates.

    Systemic Lupus Erythematosus

    Area of Research

    Phase*

    Afimetoran
    TLR 7/8 Inhibitor
    Area of Research: Systemic Lupus Erythematosus
    Phase 2
    • View trial
      Save trial
    Clinical Trials For: Afimetoran, TLR 7/8 Inhibitor in Systemic Lupus Erythematosus
    • A Study Evaluating the Efficacy and Safety of BMS-986256 Compared With Placebo in Participants With Active Systemic Lupus Erythematosus (SLE)

      Recruiting, Phase 2

      NCT04895696
      NCT04895696
    Branebrutinib
    BTK Inhibitor
    Area of Research: Systemic Lupus Erythematosus
    Phase 2
    • View trial
      Save trial
    Clinical Trials For: Branebrutinib, BTK Inhibitor in Systemic Lupus Erythematosus
    • Study to Assess Safety and Effectiveness of Branebrutinib Treatment in Participants With Active Systemic Lupus Erythematosus or Primary Sjögren's Syndrome, or Branebrutinib Treatment Followed by Open-label Abatacept Treatment in Study Participants With Active Rheumatoid Arthritis

      Recruiting, Phase 2

      NCT04186871
      NCT04186871
    Expand All Displaying 5 of 11

    Systemic Lupus Erythematosus

    No trials are available at this time. Check back for updates.

    Ulcerative Colitis

    Area of Research

    Phase*

    Deucravacitinib
    TYK2i
    Area of Research: Moderate to Severe Ulcerative Colitis
    Phase 2
    • View trial
      Save trial
    Clinical Trials For: Deucravacitinib, TYK2i in Moderate to Severe Ulcerative Colitis
    • A Study to Evaluate the Long-term Safety and Efficacy of BMS-986165 in Participants With Crohn's Disease or Ulcerative Colitis

      Recruiting, Phase 2

      NCT04877990
      NCT04877990
    Deucravacitinib
    TYK2i
    Area of Research: Ulcerative Colitis
    Phase 2
    • View trial
      Save trial
    Clinical Trials For: Deucravacitinib, TYK2i in Ulcerative Colitis
    • A Study of the Safety, Efficacy, and Biomarker Response of BMS-986165 in Participants With Moderate to Severe Ulcerative Colitis

      Recruiting, Phase 2

      NCT04613518
      NCT04613518
    Ozanimod
    S1P1R Modulator
    Area of Research: Moderate to Severe Active Ulcerative Colitis
    Phase 3
    • View trial
      Save trial
    Clinical Trials For: Ozanimod, S1P1R Modulator in Moderate to Severe Active Ulcerative Colitis
    • To Evaluate Efficacy and Long-term Safety of Ozanimod in Japanese Subjects With Moderately to Severely Active Ulcerative Colitis

      Recruiting, Phase 3

      NCT03915769
      NCT03915769
    Ozanimod
    S1P1R Modulator
    Area of Research: Pediatric Participants With Moderate to Severe Active Ulcerative Colitis
    Phase 2/3
    • View trial
      Save trial
    Clinical Trials For: Ozanimod, S1P1R Modulator in Pediatric Participants With Moderate to Severe Active Ulcerative Colitis
    • A Study Investigating Oral Ozanimod (RPC1063) in Pediatric Participants With Moderate to Severe Active Ulcerative Colitis

      Not Yet Recruiting, Phase 2/3

      NCT05076175
      NCT05076175
    Expand All Displaying 5 of 11

    Ulcerative Colitis

    No trials are available at this time. Check back for updates.

    Neuroscience

    Neuroscience (General)

    Area of Research

    Phase*

    Expand All Displaying 5 of 11

    No results were found. Please try another search query. If you do not see the results you are looking for, please visit BolderScience.com to search across the full ClinicalTrials.gov database.

    Solid Tumors

    Bladder

    Area of Research

    Phase*

    Nivolumab ± Bempegaldesleukin
    Anti–PD-1 ± CD-122-biased Preferential IL-2 Receptor Pathway Agonist
    Area of Research: Perioperative MIBC
    Phase 3
    • View trial
      Save trial
    Clinical Trials For: Nivolumab ± Bempegaldesleukin, Anti–PD-1 ± CD-122-biased Preferential IL-2 Receptor Pathway Agonist in Perioperative MIBC
    • A Study of Nivolumab Plus Bempegaldesleukin (Bempeg/NKTR-214) vs Nivolumab Alone vs Standard of Care in Participants With Bladder Cancer That Has Invaded the Muscle Wall of the Bladder and Who Cannot Get Cisplatin, a Type of Medicine Given to Treat Bladder Cancer

      Recruiting, Phase 3

      NCT04209114
      NCT04209114
    Nivolumab + Chemotherapy
    Anti–PD-1 + Chemotherapy ± IDO1 Inhibitor
    Area of Research: Perioperative MIBC
    Phase 3
    • View trial
      Save trial
    Clinical Trials For: Nivolumab + Chemotherapy, Anti–PD-1 + Chemotherapy ± IDO1 Inhibitor in Perioperative MIBC
    • A Study of Chemotherapy Only Versus Chemotherapy Plus Nivo With or Without BMS-986205, Followed by Post- Surgery Therapy With Nivo or Nivo and BMS-986205 in Patients With MIBC

      Recruiting, Phase 3

      NCT03661320
      NCT03661320
    Nivolumab + Ipilimumab or Chemotherapy
    Anti–PD-1 + Anti–CTLA-4 or Chemotherapy
    Area of Research: 1L Unresectable or Metastatic Urothelial Carcinoma
    Phase 3
    • View trial
      Save trial
    Clinical Trials For: Nivolumab + Ipilimumab or Chemotherapy, Anti–PD-1 + Anti–CTLA-4 or Chemotherapy in 1L Unresectable or Metastatic Urothelial Carcinoma
    • Study of Nivolumab in Combination With Ipilimumab or Standard of Care Chemotherapy Compared to the Standard of Care Chemotherapy Alone in Treatment of Participants With Untreated Inoperable or Metastatic Urothelial Cancer

      Recruiting, Phase 3

      NCT03036098
      NCT03036098
    Expand All Displaying 5 of 11

    Bladder

    No trials are available at this time. Check back for updates.

    Breast

    Area of Research

    Phase*

    Expand All Displaying 5 of 11

    Breast

    No trials are available at this time. Check back for updates.

    Colorectal

    Area of Research

    Phase*

    Nivolumab ± Ipilimumab
    Anti–PD-1 ± Anti–CTLA-4
    Area of Research: 1L+ Recurrent or Metastatic
    MSI-H/dMMR CRC
    Phase 3
    • View trial
      Save trial
    Clinical Trials For: Nivolumab ± Ipilimumab, Anti–PD-1 ± Anti–CTLA-4 in 1L+ Recurrent or Metastatic
    MSI-H/dMMR CRC
    • A Study of Nivolumab, Nivolumab Plus Ipilimumab, or Investigator's Choice Chemotherapy for the Treatment of Participants With Deficient Mismatch Repair (dMMR)/Microsatellite Instability High (MSI-H) Metastatic Colorectal Cancer (mCRC)

      Recruiting, Phase 3

      NCT04008030
      NCT04008030
    Nivolumab + MEK Inhibitor ± Ipilimumab
    Anti–PD-1 + MEK Inhibitor ± Anti–CTLA-4
    Area of Research: 2L+ mCRC
    Phase 1/2
    • View trial
      Save trial
    Clinical Trials For: Nivolumab + MEK Inhibitor ± Ipilimumab, Anti–PD-1 + MEK Inhibitor ± Anti–CTLA-4 in 2L+ mCRC
    • An Investigational Immuno-therapy Study Of Nivolumab In Combination With Trametinib With Or Without Ipilimumab In Participants With Previously Treated Cancer of the Colon or Rectum That Has Spread

      Recruiting, Phase 1/2

      NCT03377361
      NCT03377361
    Expand All Displaying 5 of 11

    Colorectal

    No trials are available at this time. Check back for updates.

    Esophageal, Gastroesophageal

    Area of Research

    Phase*

    Expand All Displaying 5 of 11

    Esophageal, Gastroesophageal

    No trials are available at this time. Check back for updates.

    Gastric

    Area of Research

    Phase*

    Expand All Displaying 5 of 11

    Gastric

    No trials are available at this time. Check back for updates.

    Glioblastoma

    Area of Research

    Phase*

    CC-90010 + Chemotherapy ± RT
    BET Inhibitor + Chemotherapy ± RT
    Area of Research: Newly Diagnosed Glioblastoma
    Phase 1
    • View trial
      Save trial
    Clinical Trials For: CC-90010 + Chemotherapy ± RT, BET Inhibitor + Chemotherapy ± RT in Newly Diagnosed Glioblastoma
    • A Study of CC-90010 in Combination With Temozolomide With or Without Radiation Therapy in Subjects Patients With Newly Diagnosed Glioblastoma

      Recruiting, Phase 1

      NCT04324840
      NCT04324840
    Expand All Displaying 5 of 11

    Glioblastoma

    No trials are available at this time. Check back for updates.

    Head & Neck

    Area of Research

    Phase*

    Expand All Displaying 5 of 11

    Head & Neck

    No trials are available at this time. Check back for updates.

    Hepatocellular Carcinoma

    Area of Research

    Phase*

    Nivolumab ± Relatlimab
    Anti–PD-1 ± Anti–LAG-3
    Area of Research: Advanced HCC
    Phase 2
    • View trial
      Save trial
    Clinical Trials For: Nivolumab ± Relatlimab, Anti–PD-1 ± Anti–LAG-3 in Advanced HCC
    • A Study of Relatlimab in Combination With Nivolumab in Participants With Advanced Liver Cancer Who Have Never Been Treated With Immuno-oncology Therapy After Prior Treatment With Tyrosine Kinase Inhibitors

      Recruiting, Phase 2

      NCT04567615
      NCT04567615
    Expand All Displaying 5 of 11

    Hepatocellular Carcinoma

    No trials are available at this time. Check back for updates.

    Lung

    Area of Research

    Phase*

    CC-90011 + Chemotherapy ± Nivolumab
    LSD1 Inhibitor + Chemotherapy ± Anti–PD-1
    Area of Research: 1L Extensive Stage SCLC
    Phase 1
    • View trial
      Save trial
    Clinical Trials For: CC-90011 + Chemotherapy ± Nivolumab, LSD1 Inhibitor + Chemotherapy ± Anti–PD-1 in 1L Extensive Stage SCLC
    • A Safety, Tolerability and Preliminary Efficacy Evaluation of CC-90011 Given in Combination With Cisplatin and Etoposide in Subjects With First Line, Extensive Stage Small Cell Lung Cancer

      Recruiting, Phase 1

      NCT03850067
      NCT03850067
    Neoadjuvant Nivolumab + Chemotherapy, Followed by Adjuvant Nivolumab
    Anti–PD-1 + Chemotherapy
    Area of Research: Resectable NSCLC
    Phase 3
    • View trial
      Save trial
    Clinical Trials For: Neoadjuvant Nivolumab + Chemotherapy, Followed by Adjuvant Nivolumab, Anti–PD-1 + Chemotherapy in Resectable NSCLC
    • A Study of Neoadjuvant Chemotherapy Plus Nivolumab Versus Neoadjuvant Chemotherapy Plus Placebo, Followed by Surgical Removal and Adjuvant Treatment With Nivolumab or Placebo for Participants With Surgically Removable Early Stage Non-small Cell Lung Cancer

      Recruiting, Phase 3

      NCT04025879
      NCT04025879
    Nivolumab + Chemotherapy ±
    BMS-986012
    Anti–PD-1 + Chemotherapy ± Anti–FucGM1
    Area of Research: 1L ES-SCLC
    Phase 2
    • View trial
      Save trial
    Clinical Trials For: Nivolumab + Chemotherapy ±
    BMS-986012, Anti–PD-1 + Chemotherapy ± Anti–FucGM1 in 1L ES-SCLC
    • A Study of BMS-986012 in Combination With Carboplatin, Etoposide, and Nivolumab as First-line Therapy in Extensive-stage Small Cell Lung Cancer

      Recruiting, Phase 2

      NCT04702880
      NCT04702880
    Nivolumab + Chemotherapy ± Relatlimab
    Anti–PD-1 + Chemotherapy ± Anti–LAG-3
    Area of Research: 1L Stage IV or Recurrent NSCLC
    Phase 2
    • View trial
      Save trial
    Clinical Trials For: Nivolumab + Chemotherapy ± Relatlimab, Anti–PD-1 + Chemotherapy ± Anti–LAG-3 in 1L Stage IV or Recurrent NSCLC
    • A Study of Relatlimab Plus Nivolumab in Combination With Chemotherapy vs. Nivolumab in Combination With Chemotherapy as First Line Treatment for Participants With Stage IV or Recurrent Non-small Cell Lung Cancer (NSCLC)

      Recruiting, Phase 2

      NCT04623775
      NCT04623775
    Nivolumab + Chemotherapy + RT, Followed by Maintenance Nivolumab ± Ipilimumab
    Anti–PD-1 ± Anti–CTLA-4
    Area of Research: Locally Advanced NSCLC Amenable to cCRT
    Phase 3
    • View trial
      Save trial
    Clinical Trials For: Nivolumab + Chemotherapy + RT, Followed by Maintenance Nivolumab ± Ipilimumab, Anti–PD-1 ± Anti–CTLA-4 in Locally Advanced NSCLC Amenable to cCRT
    • A Study of Nivolumab and Ipilimumab in Untreated Patients With Stage 3 Non-small Cell Lung Cancer (NSCLC) That is Unable or Not Planned to be Removed by Surgery

      Recruiting, Phase 3

      NCT04026412
      NCT04026412
    Nivolumab + Ipilimumab ±
    BMS-986207
    Anti–PD-1 + CTLA-4 ± Anti-TIGIT
    Area of Research: 1L Stage IV NSCLC
    Phase 2
    • View trial
      Save trial
    Clinical Trials For: Nivolumab + Ipilimumab ±
    BMS-986207, Anti–PD-1 + CTLA-4 ± Anti-TIGIT in 1L Stage IV NSCLC
    • A Study to Assess BMS-986207 in Combination With Nivolumab and Ipilimumab as First-line Treatment for Participants With Stage IV Non-Small Cell Lung Cancer

      Not Yet Recruiting, Phase 2

      NCT05005273
      NCT05005273
    Expand All Displaying 5 of 11

    Lung

    No trials are available at this time. Check back for updates.

    Melanoma

    Area of Research

    Phase*

    Nivolumab ± Relatlimab
    Anti–PD-1 ± Anti–LAG-3
    Area of Research: Completely Resected Stage III-IV Melanoma
    Phase 3
    • View trial
      Save trial
    Clinical Trials For: Nivolumab ± Relatlimab, Anti–PD-1 ± Anti–LAG-3 in Completely Resected Stage III-IV Melanoma
    • A Study to Assess Adjuvant Immunotherapy With Relatlimab and Nivolumab Versus Nivolumab Alone After Complete Resection of Stage III-IV Melanoma

      Recruiting, Phase 3

      NCT05002569
      NCT05002569
    Relatlimab ± Ipilimumab
    Anti–LAG-3 ± Anti–CTLA-4
    Area of Research: Advanced or Unresectable Melanoma Patients Who Have Progressed on/After
    Anti–PD-L1 Therapy
    Phase 1/2
    • View trial
      Save trial
    Clinical Trials For: Relatlimab ± Ipilimumab, Anti–LAG-3 ± Anti–CTLA-4 in Advanced or Unresectable Melanoma Patients Who Have Progressed on/After
    Anti–PD-L1 Therapy
    • A Study to Assess Safety and Efficacy of Relatlimab With Ipilimumab in Participants With Advanced Melanoma Who Progressed on Anti–PD-1 Treatment

      Recruiting, Phase 1/2

      NCT03978611
      NCT03978611
    Expand All Displaying 5 of 11

    Melanoma

    No trials are available at this time. Check back for updates.

    Mesothelioma

    Area of Research

    Phase*

    Nivolumab + Ipilimumab
    Anti–PD-1 + Anti–CTLA-4
    Area of Research: Unresectable Pleural Mesothelioma
    Phase 2
    • View trial
      Save trial
    Clinical Trials For: Nivolumab + Ipilimumab, Anti–PD-1 + Anti–CTLA-4 in Unresectable Pleural Mesothelioma
    • A Study to Evaluate Nivolumab in Combination With Ipilimumab Versus Pemetrexed With Cisplatin or Carboplatin for Unresectable Pleural Mesothelioma in Chinese Participants

      Recruiting, Phase 2

      NCT05136677
      NCT05136677
    Expand All Displaying 5 of 11

    Mesothelioma

    No trials are available at this time. Check back for updates.

    Ovarian

    Area of Research

    Phase*

    Expand All Displaying 5 of 11

    Ovarian

    No trials are available at this time. Check back for updates.

    Pan-Tumor TMB High

    Area of Research

    Phase*

    Expand All Displaying 5 of 11

    Pan-Tumor TMB High

    No trials are available at this time. Check back for updates.

    Pediatric

    Area of Research

    Phase*

    Expand All Displaying 5 of 11

    Pediatric

    No trials are available at this time. Check back for updates.

    Prostate

    Area of Research

    Phase*

    CC-90011 + Anti-androgen + Steroid
    LSD1 Inhibitor + Anti-androgen + Steroid
    Area of Research: Metastatic CRPC
    Phase 1
    • View trial
      Save trial
    Clinical Trials For: CC-90011 + Anti-androgen + Steroid, LSD1 Inhibitor + Anti-androgen + Steroid in Metastatic CRPC
    • A Study of CC-90011 and Comparators in Participants With Prostate Cancer

      Recruiting, Phase 1

      NCT04628988
      NCT04628988
    CC-94676
    AR-LDD
    Area of Research: Metastatic CRPC
    Phase 1
    • View trial
      Save trial
    Clinical Trials For: CC-94676, AR-LDD in Metastatic CRPC
    • Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of CC-94676 in Subjects With Metastatic Castration-Resistant Prostate Cancer

      Recruiting, Phase 1

      NCT04428788
      NCT04428788
    Nivolumab + Chemotherapy + Steroid
    Anti–PD-1 + Chemotherapy + Steroid
    Area of Research: 2L+ mCRPC
    Phase 3
    • View trial
      Save trial
    Clinical Trials For: Nivolumab + Chemotherapy + Steroid, Anti–PD-1 + Chemotherapy + Steroid in 2L+ mCRPC
    • A Study of Nivolumab or Placebo in Combination With Docetaxel in Men With Advanced Castration-resistant Prostate Cancer

      Recruiting, Phase 3

      NCT04100018
      NCT04100018
    Expand All Displaying 5 of 11

    Prostate

    No trials are available at this time. Check back for updates.

    Renal Cell Carcinoma

    Area of Research

    Phase*

    Nivolumab ± Hyaluronidase
    Anti–PD-1
    Area of Research: Advanced or mccRCC
    Phase 3
    • View trial
      Save trial
    Clinical Trials For: Nivolumab ± Hyaluronidase, Anti–PD-1 in Advanced or mccRCC
    • A Study of Subcutaneous Nivolumab Versus Intravenous Nivolumab in Participants With Previously Treated Clear Cell Renal Cell Carcinoma That is Advanced or Has Spread

      Recruiting, Phase 3

      NCT04810078
      NCT04810078
    Nivolumab + Ipilimumab
    Anti–PD-1 + CTLA-4
    Area of Research: Advanced Renal Cell Carcinoma and Intermediate- or Poor-risk Factors
    Phase 4
    • View trial
      Save trial
    Clinical Trials For: Nivolumab + Ipilimumab, Anti–PD-1 + CTLA-4 in Advanced Renal Cell Carcinoma and Intermediate- or Poor-risk Factors
    • A Combination Study of Nivolumab With Ipilimumab in Participants With Untreated Advanced Kidney Cancer Conducted in India

      Recruiting, Phase 4

      NCT04513522
      NCT04513522
    Nivolumab + TKI + Bempegaldesleukin
    Anti–PD-1 + TKI + CD-122-Preferential IL-2 Pathway Agonist
    Area of Research: Advanced or mRCC
    Phase 1/2
    • View trial
      Save trial
    Clinical Trials For: Nivolumab + TKI + Bempegaldesleukin, Anti–PD-1 + TKI + CD-122-Preferential IL-2 Pathway Agonist in Advanced or mRCC
    • A Study to Compare Bempegaldesleukin (BEMPEG: NKTR-214) Combined With Nivolumab and Tyrosine Kinase Inhibitor (TKI) to Nivolumab and TKI Alone in Participants With Previously Untreated Kidney Cancer That is Advanced or Has Spread

      Recruiting, Phase 1/2

      NCT04540705
      NCT04540705
    Expand All Displaying 5 of 11

    Renal Cell Carcinoma

    No trials are available at this time. Check back for updates.

    Solid Tumors (General)

    Area of Research

    Phase*

    AGEN1777 ±
    Anti–PD-1
    TIGIT Bispecific ± Anti–PD-1
    Area of Research: Advanced Solid Tumors
    Phase 1
    • View trial
      Save trial
    Clinical Trials For: AGEN1777 ±
    Anti–PD-1, TIGIT Bispecific ± Anti–PD-1 in Advanced Solid Tumors
    • A Study Investigating AGEN1777 in Participants With Advanced Solid Tumors

      Recruiting, Phase 1

      NCT05025085
      NCT05025085
    BMS-986207
    Anti-TIGIT
    Area of Research: Advanced Solid Tumors
    Phase 1/2
    • View trial
      Save trial
    Clinical Trials For: BMS-986207, Anti-TIGIT in Advanced Solid Tumors
    • An Investigational Immuno-therapy Study of BMS-986207 Given Alone and in Combination With Nivolumab or With Nivolumab and Ipilimumab in Solid Cancers That Are Advanced or Have Spread

      Recruiting, Phase 1/2

      NCT02913313
      NCT02913313
    BMS-986207 + Nivolumab ± Ipilimumab
    Anti-TIGIT + Anti–PD-1 ± CTLA-4
    Area of Research: Advanced Solid Tumors
    Phase 1/2
    • View trial
      Save trial
    Clinical Trials For: BMS-986207 + Nivolumab ± Ipilimumab, Anti-TIGIT + Anti–PD-1 ± CTLA-4 in Advanced Solid Tumors
    • An Investigational Immuno-therapy Study of BMS-986207 Given Alone and in Combination With Nivolumab or With Nivolumab and Ipilimumab in Solid Cancers That Are Advanced or Have Spread

      Recruiting, Phase 1/2

      NCT02913313
      NCT02913313
    BMS-986213
    Anti–PD-1 + Anti–LAG-3
    Area of Research: Advanced Solid Tumors
    Phase 1/2
    • View trial
      Save trial
    Clinical Trials For: BMS-986213, Anti–PD-1 + Anti–LAG-3 in Advanced Solid Tumors
    • A Study to Assess Relatlimab in Combination With Nivolumab in Chinese Participants With Advanced Solid Tumors

      Recruiting, Phase 1/2

      NCT05134948
      NCT05134948
    BMS-986218 ± Nivolumab
    Anti–CTLA-4–NF ± Anti–PD-1
    Area of Research: Advanced Solid Tumors
    Phase 1/2
    • View trial
      Save trial
    Clinical Trials For: BMS-986218 ± Nivolumab, Anti–CTLA-4–NF ± Anti–PD-1 in Advanced Solid Tumors
    • First-In-Human Study of Monoclonal Antibody BMS-986218 by Itself and in Combination With Nivolumab in Participants With Advanced Solid Tumors

      Recruiting, Phase 1/2

      NCT03110107
      NCT03110107
    BMS-986249 ± Nivolumab
    Anti–CTLA-4 Probody ± Anti–PD-1
    Area of Research: Advanced Solid Tumors
    Phase 1/2
    • View trial
      Save trial
    Clinical Trials For: BMS-986249 ± Nivolumab, Anti–CTLA-4 Probody ± Anti–PD-1 in Advanced Solid Tumors
    • An Investigational Immunotherapy Study of BMS-986249 Alone and in Combination With Nivolumab in Solid Cancers That Are Advanced or Have Spread

      Recruiting, Phase 1/2

      NCT03369223
      NCT03369223
    BMS-986253 + Nivolumab ± Ipilimumab
    Anti–IL-8 + Anti–PD-1 ± Anti–CTLA-4
    Area of Research: Advanced Solid Tumors
    Phase 1/2
    • View trial
      Save trial
    Clinical Trials For: BMS-986253 + Nivolumab ± Ipilimumab, Anti–IL-8 + Anti–PD-1 ± Anti–CTLA-4 in Advanced Solid Tumors
    • A Study of BMS-986253 in Combination With Nivolumab or Nivolumab Plus Ipilimumab in Advanced Cancers

      Recruiting, Phase 1/2

      NCT03400332
      NCT03400332
    BMS-986288 ± Nivolumab
    Anti–CTLA-4–NF Probody ± Anti–PD-1
    Area of Research: Advanced Solid Tumors
    Phase 1/2
    • View trial
      Save trial
    Clinical Trials For: BMS-986288 ± Nivolumab, Anti–CTLA-4–NF Probody ± Anti–PD-1 in Advanced Solid Tumors
    • An Investigational Immunotherapy Study of BMS-986288 Alone and in Combination With Nivolumab in Advanced Solid Cancers

      Recruiting, Phase 1/2

      NCT03994601
      NCT03994601
    BMS-986299 ± Nivolumab + Ipilimumab
    NLRP3 Agonist ± Anti–PD-1 + Anti–CTLA-4
    Area of Research: Advanced Solid Tumors
    Phase 1
    • View trial
      Save trial
    Clinical Trials For: BMS-986299 ± Nivolumab + Ipilimumab, NLRP3 Agonist ± Anti–PD-1 + Anti–CTLA-4 in Advanced Solid Tumors
    • An Investigational Immunotherapy Study of BMS-986299 Alone and in Combination With Nivolumab and Ipilimumab in Participants With Solid Cancers That Have Spread or Cannot be Removed

      Recruiting, Phase 1

      NCT03444753
      NCT03444753
    BMS-986301
    STING Agonist
    Area of Research: Advanced Solid Tumors
    Phase 1
    • View trial
      Save trial
    Clinical Trials For: BMS-986301, STING Agonist in Advanced Solid Tumors
    • An Investigational Immunotherapy Study of BMS-986301 Alone or in Combination With Nivolumab, and Ipilimumab in Participants With Advanced Solid Cancers

      Recruiting, Phase 1

      NCT03956680
      NCT03956680
    BMS-986301 + Nivolumab + Ipilimumab
    STING Agonist + Anti–PD-1 ± Anti–CTLA-4
    Area of Research: Advanced Solid Tumors
    Phase 1
    • View trial
      Save trial
    Clinical Trials For: BMS-986301 + Nivolumab + Ipilimumab, STING Agonist + Anti–PD-1 ± Anti–CTLA-4 in Advanced Solid Tumors
    • An Investigational Immunotherapy Study of BMS-986301 Alone or in Combination With Nivolumab, and Ipilimumab in Participants With Advanced Solid Cancers

      Recruiting, Phase 1

      NCT03956680
      NCT03956680
    BMS-986315 ± EGFR Inhibitor
    Anti–NKG2A ± EGFR Inhibitor
    Area of Research: Advanced Solid Tumors
    Phase 1/2
    • View trial
      Save trial
    Clinical Trials For: BMS-986315 ± EGFR Inhibitor, Anti–NKG2A ± EGFR Inhibitor in Advanced Solid Tumors
    • Study of BMS-986315 Alone and in Combination With Nivolumab or Cetuximab in Participants With Advanced Solid Tumors

      Recruiting, Phase 1/2

      NCT04349267
      NCT04349267
    BMS-986315 ± Nivolumab
    Anti-NKG2A ± Anti–PD-1
    Area of Research: Advanced Solid Tumors
    Phase 1/2
    • View trial
      Save trial
    Clinical Trials For: BMS-986315 ± Nivolumab, Anti-NKG2A ± Anti–PD-1 in Advanced Solid Tumors
    • Study of BMS-986315 Alone and in Combination With Nivolumab or Cetuximab in Participants With Advanced Solid Tumors

      Recruiting, Phase 1/2

      NCT04349267
      NCT04349267
    BMS-986340 ± Nivolumab
    Anti-CCR8 ± Anti–PD-1
    Area of Research: Advanced Solid Tumors
    Phase 1/2
    • View trial
      Save trial
    Clinical Trials For: BMS-986340 ± Nivolumab, Anti-CCR8 ± Anti–PD-1 in Advanced Solid Tumors
    • A Study of BMS-986340 as Monotherapy and in Combination With Nivolumab in Participants With Advanced Solid Tumors

      Recruiting, Phase 1/2

      NCT04895709
      NCT04895709
    BMS-986415 ± Nivolumab
    IL-12 Fc ± Anti–PD-1
    Area of Research: Advanced Solid Tumors
    Phase 1/2
    • View trial
      Save trial
    Clinical Trials For: BMS-986415 ± Nivolumab, IL-12 Fc ± Anti–PD-1 in Advanced Solid Tumors
    • Dose Escalation of DF6002 in Patients With Advanced Solid Tumors, and Expansion in Selected Indications

      Recruiting, Phase 1/2

      NCT04423029
      NCT04423029
    BMS-986416 ± Nivolumab
    TGFβi ± Anti–PD-1
    Area of Research: Select Solid Tumors
    Phase 1
    • View trial
      Save trial
    Clinical Trials For: BMS-986416 ± Nivolumab, TGFβi ± Anti–PD-1 in Select Solid Tumors
    • A Study of BMS-986416 With and Without Nivolumab in Select Solid Tumors

      Recruiting, Phase 1

      NCT04943900
      NCT04943900
    CC-90011
    LSD1 Inhibitor
    Area of Research: Advanced Solid Tumors
    Phase 1
    • View trial
      Save trial
    Clinical Trials For: CC-90011, LSD1 Inhibitor in Advanced Solid Tumors
    • A Safety and Efficacy Study of CC-90011 in Subjects With Relapsed and/or Refractory Solid Tumors and Non-Hodgkin's Lymphomas

      Recruiting, Phase 1

      NCT02875223
      NCT02875223
    CC-95251
    Anti-SIRPα
    Area of Research: Advanced Solid Tumors
    Phase 1
    • View trial
      Save trial
    Clinical Trials For: CC-95251, Anti-SIRPα in Advanced Solid Tumors
    • A Study of CC-95251, a Monoclonal Antibody Directed Against SIRPα, in Subjects With Advanced Solid and Hematologic Cancers

      Recruiting, Phase 1

      NCT03783403
      NCT03783403
    CC-95251 + Anti–CD-20
    Anti-SIRPα + Anti–CD-20
    Area of Research: Advanced Solid Tumors
    Phase 1
    • View trial
      Save trial
    Clinical Trials For: CC-95251 + Anti–CD-20, Anti-SIRPα + Anti–CD-20 in Advanced Solid Tumors
    • A Study of CC-95251, a Monoclonal Antibody Directed Against SIRPα, in Subjects With Advanced Solid and Hematologic Cancers

      Recruiting, Phase 1

      NCT03783403
      NCT03783403
    CC-95251 + EGFR Inhibitor
    Anti-SIRPα + EGFR Inhibitor
    Area of Research: Advanced Solid Tumors
    Phase 1
    • View trial
      Save trial
    Clinical Trials For: CC-95251 + EGFR Inhibitor, Anti-SIRPα + EGFR Inhibitor in Advanced Solid Tumors
    • A Study of CC-95251, a Monoclonal Antibody Directed Against SIRPα, in Subjects With Advanced Solid and Hematologic Cancers

      Recruiting, Phase 1

      NCT03783403
      NCT03783403
    IK-175 ± Nivolumab
    AHR Antagonist ± Anti–PD-1
    Area of Research: Advanced Solid Tumors and UC
    Phase 1
    • View trial
      Save trial
    Clinical Trials For: IK-175 ± Nivolumab, AHR Antagonist ± Anti–PD-1 in Advanced Solid Tumors and UC
    • A Phase 1a/b Study of IK-175 as a Single Agent and in Combination With Nivolumab in Patients With Locally Advanced or Metastatic Solid Tumors and Urothelial Carcinoma

      Recruiting, Phase 1

      NCT04200963
      NCT04200963
    Nivolumab
    Anti–PD-1
    Area of Research: Pan-tumor Study for Long-term Follow-up
    Phase 2
    • View trial
      Save trial
    Clinical Trials For: Nivolumab, Anti–PD-1 in Pan-tumor Study for Long-term Follow-up
    • Pan Tumor Nivolumab Rollover Study

      Recruiting, Phase 2

      NCT03899155
      NCT03899155
    Nivolumab + Bempegaldesleukin
    Anti–PD-1 + CD-122-Preferential IL-2 Pathway Agonist
    Area of Research: Children, Adolescents, and Young Adults With R/R Malignancies
    Phase 1/2
    • View trial
      Save trial
    Clinical Trials For: Nivolumab + Bempegaldesleukin, Anti–PD-1 + CD-122-Preferential IL-2 Pathway Agonist in Children, Adolescents, and Young Adults With R/R Malignancies
    • A Study of Bempegaldesleukin (BEMPEG: NKTR-214) in Combination With Nivolumab in Children, Adolescents and Young Adults With Recurrent or Treatment-resistant Cancer

      Recruiting, Phase 1/2

      NCT04730349
      NCT04730349
    Nivolumab ± Hyaluronidase
    Anti–PD-1 ± Hyaluronidase
    Area of Research: Advanced Solid Tumors
    Phase 1/2
    • View trial
      Save trial
    Clinical Trials For: Nivolumab ± Hyaluronidase, Anti–PD-1 ± Hyaluronidase in Advanced Solid Tumors
    • A Study of Subcutaneous Nivolumab Monotherapy With or Without Recombinant Human Hyaluronidase PH20 (rHuPH20)

      Recruiting, Phase 1/2

      NCT03656718
      NCT03656718
    Relatlimab + Nivolumab + Ipilimumab
    Anti–LAG-3 + Anti–PD-1 + Anti–CTLA-4
    Area of Research: Advanced Solid Tumors
    Phase 1/2
    • View trial
      Save trial
    Clinical Trials For: Relatlimab + Nivolumab + Ipilimumab, Anti–LAG-3 + Anti–PD-1 + Anti–CTLA-4 in Advanced Solid Tumors
    • An Investigational Study of Immunotherapy Combinations in Participants With Solid Cancers That Are Advanced or Have Spread

      Recruiting, Phase 1/2

      NCT03459222
      NCT03459222
    Relatlimab + Nivolumab + Linrodostat
    Anti–LAG-3 + Anti–PD-1 + IDO1 Inhibitor
    Area of Research: Advanced Solid Tumors
    Phase 1/2
    • View trial
      Save trial
    Clinical Trials For: Relatlimab + Nivolumab + Linrodostat, Anti–LAG-3 + Anti–PD-1 + IDO1 Inhibitor in Advanced Solid Tumors
    • An Investigational Study of Immunotherapy Combinations in Participants With Solid Cancers That Are Advanced or Have Spread

      Recruiting, Phase 1/2

      NCT03459222
      NCT03459222
    Expand All Displaying 5 of 11

    Solid Tumors (General)

    No trials are available at this time. Check back for updates.

    Looking for more clinical trials?

    Bolder Science contains all clinical trials available on ClinicalTrials.gov, including BMS trials.

    Visit BolderScience.com to search all trials worldwide.

    Powered by ClinicalTrials.gov

    close-icon

    Save trial Create an account to:

    • Save and organize trials
    • Search clinical trials
      by patient type
    • Build a dashboard
    And more!
    Create an Account
    Already have a Bolder Science account? Log In

    : Development partnerships include:

    • Apixaban: Pfizer
    • BMS-986414, BMS-986413: Rockefeller University
    • BMS-986263: Nitto Denko
    • Bempegaldesleukin: Nektar
    • Idecabtagene vicleucel (Ide-cel, bb2121) in collaboration with 2seventy bioTM
    • IK-175: Ikena Oncology
    • AGEN1777: Agenus
    • Hyaluronidase (rHuPH20): Halozyme Therapeutics
    • BMS-986415: Dragonfly Therapeutics

    1L=first line; 1L+=1L and above; 2L=second line; 2L+=2L and above; 3L=third line; 3L+=3L and above; 4L=fourth line; 4L+=4L and above; ADC=antibody-drug conjugate; AS=ankylosing spondylitis; B-ALL=B-cell acute lymphocytic leukemia; BH3=BCL-2 homology 3; BTK=Bruton’s tyrosine kinase; cCRT=concurrent chemoradiotherapy; CD=cluster of differentiation; cHL=classical Hodgkin lymphoma; CLL=chronic lymphocytic leukemia; CRC=colorectal cancer; CRPC=castration-resistant prostate cancer; CSF1=colony-stimulating factor 1; DLBCL=diffuse large B-cell lymphoma; DLE=discoid lupus erythematosus; DMARD=disease-modifying antirheumatic drug; dMMR=mismatch repair deficient; EGFR=epidermal growth factor receptor; ESA=erythropoiesis-stimulating agent; ES-SCLC=extensive-stage small cell lung cancer; ET=essential thrombocytopenia; FL=follicular lymphoma; HCC=hepatocellular carcinoma; mccRCC=metastatic clear-cell renal cell carcinoma; MCL=mantle cell lymphoma; mCRC=metastatic colorectal cancer; mCRPC=metastatic castration-resistant prostate cancer; MDS=myelodysplastic syndrome; MDS-RS=myelodysplastic syndrome with ring sideroblasts; MF=myelofibrosis; MIBC=muscle-invasive bladder cancer; MM=multiple myeloma; mRCC=metastatic renal cell carcinoma; MSI-H=microsatellite instability-high; NASH=nonalcoholic steatohepatitis; NDMM=newly diagnosed multiple myeloma; NHL=non-Hodgkin lymphoma; NSCLC=non-small cell lung cancer; PMF=primary myelofibrosis; PsA=psoriatic arthritis; PV=polycythemia vera; R/R=relapsed/refractory; RA=rheumatoid arthritis; RCC=renal cell carcinoma; SCLC=small cell lung cancer; SCLE=subacute cutaneous lupus erythematosus; SIRPα=CD47-signal regulatory protein alpha; sqNSCLC=squamous NSCLC; TKI=tyrosine kinase inhibitor; TNFα=tumor necrosis factor alpha; UC=urothelial carcinoma; VTE=venous thromboembolism.

    Bristol Myers Squibb logo
    • Legal Notice
    • Privacy Policy
    • Contact Us
    • Sitemap
    © 2022 BMS Science 01/22 466-US-2100214 BMS Science is a registered trademark of Bristol-Myers Squibb Company.

    You are now leaving www.BMSscience.com. BMS is not responsible for the content on third-party website

    Continue Cancel
    close-icon

    Log In

    Log in below to access your account on BMS Science or Bolder Science. If you have an existing Bolder Science account, please use your login credentials for that account here.

    Forgot Password

    Don't have an account? Sign Up

    close-icon

    Please enter your email address.

    You will receive a link to create a new password via email.

    Log In

    close-icon

    Create Account

    Use the form below to create one account that will be used across both BMS Science and Bolder Science. Clinical trials that you save on either site will be shown together on your dashboard on Bolder Science. If you already have an account, you can log in here.

    • 8 characters minimum
    • First character cannot be a number
    • Last character cannot be a number

    By clicking submit, you agree to the BMS Privacy Policy and Terms & Conditions

    close-icon

    Previous Next skip